Purpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has
shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of
temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or
refractory disease.